Osmind Announces Publication of Largest Real-World Study on Effectiveness of Ketamine Intravenous Therapy for Depression, Anxiety and Suicidal Ideation

SAN FRANCISCO–(BUSINESS WIRE)–Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today announced the results of a new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy (KIT). Developed in collaboration with a team of clinicians and published in the Journal of Affective Disorders,…
Click here to view original post